Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 18, 2019Journal of Clinical OncologyOpen Access

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMichael S. KhodadoustStanford MedicineARAlain H. RookUniversity Medical CenterPPPierluigi PorcuRoswell Park Comprehensive Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Khodadoust et al. (2019) studied this question.

synapsesocial.com/papers/69d7c518f39344339dd181aahttps://doi.org/10.1200/jco.19.01056
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders2009 · 225 citations
  2. 2VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing2012 · 5,427 citations
  3. 3Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study2011 · 654 citations
  4. 4Fast and accurate short read alignment with Burrows–Wheeler transform2009 · 64,150 citations
  5. 5Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model2015 · 430 citations